BLOOD TESTING MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025 - 2032)

The global blood testing market is estimated to be valued at USD 106.10 Bn in 2025 and is expected to reach USD 192.71 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 8.9% from 2025 to 2032. The global blood testing market represents a critical segment of the healthcare diagnostics industry, encompassing a comprehensive range of laboratory tests and diagnostic procedures that analyze blood samples to detect diseases, monitor health conditions, and guide treatment decisions. Blood testing serves as a fundamental diagnostic tool across various medical specialties, including cardiology, oncology, infectious diseases, diabetes management, and routine health screenings. The market encompasses diverse testing methodologies ranging from traditional laboratory-based assays to innovative point-of-care testing devices, molecular diagnostics, and automated high-throughput systems.

With the increasing prevalence of chronic diseases such as diabetes, cardiovascular disorders, and cancer, coupled with the growing emphasis on preventive healthcare and early disease detection, the demand for blood testing services continues to expand globally. The market is characterized by rapid technological advancements, including the development of minimally invasive testing procedures, enhanced accuracy through artificial intelligence integration, and the emergence of personalized medicine approaches. Key market participants include clinical laboratories, hospitals, diagnostic centers, and point-of-care testing device manufacturers, all contributing to the market's robust growth trajectory driven by aging populations, healthcare infrastructure development, and increased healthcare awareness worldwide.

Market Dynamics

The global blood testing market is propelled by several compelling drivers that fuel its sustained growth trajectory. The primary driver stems from the escalating prevalence of chronic diseases worldwide, including diabetes, cardiovascular disorders, cancer, and infectious diseases, necessitating regular blood monitoring and diagnostic testing for effective disease management and treatment optimization. The aging global population significantly contributes to market expansion as elderly individuals require frequent health screenings and monitoring, driving demand for comprehensive blood testing services. Technological advancements represent another crucial driver, with innovations in point-of-care testing devices, automated laboratory systems, molecular diagnostics, and AI-powered diagnostic tools enhancing testing accuracy, reducing turnaround times, and improving patient outcomes.

The growing emphasis on preventive healthcare and early disease detection further accelerates market growth, as healthcare systems worldwide prioritize proactive health management strategies. However, the market faces notable restraints including high costs associated with advanced diagnostic equipment and testing procedures, which can limit accessibility, particularly in developing regions with constrained healthcare budgets. Stringent regulatory requirements and lengthy approval processes for new diagnostic tests and devices pose additional challenges, potentially delaying market entry and increasing development costs. The shortage of skilled laboratory professionals and technicians in certain regions creates operational constraints for healthcare facilities.

Nevertheless, significant opportunities emerge from the expanding applications of blood testing in personalized medicine, pharmacogenomics, and companion diagnostics, enabling tailored treatment approaches. The growing adoption of home-based and self-testing solutions presents lucrative opportunities, particularly accelerated by the COVID-19 pandemic's impact on healthcare delivery models. Emerging markets in Asia Pacific, Latin America, and Africa offer substantial growth potential driven by improving healthcare infrastructure, increasing healthcare expenditure, and rising awareness about the importance of regular health screenings and diagnostic testing.

Key Features of the Study

• This report provides in-depth analysis of the global blood testing market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global blood testing market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Abbott Laboratories, F. Hoffmann-La Roche Ltd, Siemens Healthineers, Thermo Fisher Scientific Inc., Beckman Coulter Inc. (Danaher Corporation), Bio-Rad Laboratories Inc., Becton Dickinson and Company (BD), Ortho Clinical Diagnostics, Quest Diagnostics Incorporated, PerkinElmer Inc., Grifols S.A., bioMérieux SA, Cepheid (Danaher Corporation), DiaSorin S.p.A., and Nova Biomedical
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global blood testing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global blood testing market

Market Segmentation

• Test Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Clinical Chemistry
    • Basic/Lipid Metabolic Panels
    • Electrolyte Panel
    • Liver Function Tests
    • Renal Function Tests
    • Thyroid Function Tests
    • Blood Glucose Tests
  • Hematology and Coagulation
    • Complete Blood Count (CBC)
    • Platelet Count and Function Tests
    • Prothrombin Time/International Normalized Ratio
    • Activated Partial Thromboplastin Time (aPTT)
  • Immunoassay and Serology
    • Infectious Disease Testing (HIV, Hepatitis, COVID-19, STIs)
    • Autoimmune Disease Testing
    • Allergy Testing
    • Cancer Biomarker Tests
    • Hormone Level Testing
  • Molecular Blood Tests
    • Nucleic Acid Testing (NAT) for Infectious Diseases
    • Pharmacogenomics
    • Oncology (Liquid Biopsy)
  • Microbiology
  • Blood Culture Tests
  • Gram Stains
  • Others
• Technology Insights (Revenue, USD Bn, 2020 - 2032)
  • Immunoassay
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS)
  • Microarray
  • Clinical Chemistry Analysis
  • Hematology Analyzers
  • Mass Spectrometry
  • Flow Cytometry
• Product Insights (Revenue, USD Bn, 2020 - 2032)
  • Reagents and Kits
  • Instruments and Analyzers
  • Consumables (tubes, slides, etc.)
  • Software and Services
• Application Insights (Revenue, USD Bn, 2020 - 2032)
  • Disease Diagnosis
  • Wellness and Health Monitoring
  • Therapeutic Drug Monitoring
  • Pre-Natal Screening
  • Pre-Operative Testing
  • Drug of Abuse Testing
• End User Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospitals
  • Diagnostic Laboratories
  • Blood Banks
  • Research Institutes and Academia
  • Home Care and Self-Testing Users
• Sample Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Whole Blood
  • Serum
  • Plasma
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Abbott Laboratories
  • Hoffmann-La Roche Ltd
  • Siemens Healthineers
  • Thermo Fisher Scientific Inc.
  • Beckman Coulter Inc. (Danaher Corporation)
  • Bio-Rad Laboratories Inc.
  • Becton Dickinson and Company (BD)
  • Ortho Clinical Diagnostics
  • Quest Diagnostics Incorporated
  • PerkinElmer Inc.
  • Grifols S.A.
  • bioMerieux SA
  • Cepheid (Danaher Corporation)
  • DiaSorin S.p.A.
  • Nova Biomedical